Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy

被引：0
|
作者：
Duong, Vu H. [1 ]
Jaglal, Michael V. [1 ]
Zhang, Ling [2 ]
Kale, Vishakha [3 ]
Lancet, Jeffrey E.
Komrokji, Rami S.
List, Alan F. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL 33612 USA
[3] James A Haley Vet Hosp, Tampa, FL 33612 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：752 / 753
页数：2
相关论文
共 50 条
  • [1] Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
    Duong, Vu H.
    Jaglal, Michael V.
    Zhang, Ling
    Kale, Vishakha
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    List, Alan F.
    LEUKEMIA RESEARCH, 2013, 37 (03) : 300 - 304
  • [2] Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study
    Holsinger, Aaron L.
    Ramakrishnan, Aravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Stephen
    Deeig, H. Joachim
    Scott, Bart L.
    BLOOD, 2007, 110 (11) : 435A - 435A
  • [3] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    CANCER RESEARCH, 2024, 84 (07)
  • [4] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [5] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [6] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [7] A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
    Donnellan, William Bruce
    Diez-Campelo, Maria
    Heuser, Michael
    Ritchie, Ellen K.
    Skolnik, Jeffrey
    Font, Patricia
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [9] Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
    Morita, Kiyomi
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Bodden, Kristy R.
    Wang, Feng
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Jabbour, Elias
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ohanian, Maro
    Pierce, Sherry A.
    Azab, Mohammad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [10] A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Daver, Naval G.
    Jabbour, Elias J.
    Alvarado, Yesid
    DiNardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Bose, Prithviraj
    Pemmaraju, Naveen
    Naqvi, Kiran
    Cortes, Jorge E.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Colla, Simona
    Yang, Hui
    Rausch, Caitlin R.
    Gasior, Yvonne
    Bueso-Ramos, Carlos E.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
12345